OKYO PHARMA LTD

OKYO Pharma insiders hold long‑term options, signaling confidence in future growth while signaling potential dilution – a strategic view that could shape investors’ outlook as the company advances its pre‑clinical pipeline and seeks financing.

OKYO Pharma insider report: CERRONE GABRIELE M keeps a 10‑million‑share stake, valuing his holding at ~$17M. The move signals confidence in pre‑clinical plans and a potential price rally when key milestones hit.

Insider confidence fuels OKYO Pharma’s eye‑disease pipeline—Jacob Gary S. retains 108,920 shares and options, signaling potential milestones and market upside despite a current price‑sentiment lag.